Which has better earnings & valuation, ENOV or TFX?

Teleflex has lower revenue, but higher earnings than Enovis. Teleflex is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enovis $2.25B 0.62 -$1.18B -$19.26 N/A Teleflex $1.99B 2.95 -$905.64M -$23.29 N/A

Is ENOV or TFX more profitable?

Teleflex has a net margin of -39.67% compared to Enovis' net margin of -47.96%. Enovis' return on equity of 12.03% beat Teleflex's return on equity. Company Net Margins Return on Equity Return on Assets Enovis -47.96% 12.03% 4.91% Teleflex -39.67% 11.93% 5.44%

Does the media prefer ENOV or TFX?

In the previous week, Teleflex had 3 more articles in the media than Enovis. MarketBeat recorded 27 mentions for Teleflex and 24 mentions for Enovis. Teleflex's average media sentiment score of 0.56 beat Enovis' score of 0.47 indicating that Teleflex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 3 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Teleflex 8 Very Positive mention(s) 3 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, MMED or ENOV?

MiniMed Group has higher revenue and earnings than Enovis. MiniMed Group is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiniMed Group $3.10B 1.77 -$333M -$0.68 N/A Enovis $2.25B 0.62 -$1.18B -$19.26 N/A

Is MMED or ENOV more profitable?

MiniMed Group has a net margin of 0.00% compared to Enovis' net margin of -47.96%. Enovis' return on equity of 12.03% beat MiniMed Group's return on equity. Company Net Margins Return on Equity Return on Assets MiniMed Group N/A N/A N/A Enovis -47.96% 12.03% 4.91%

Does the media favor MMED or ENOV?

In the previous week, Enovis had 23 more articles in the media than MiniMed Group. MarketBeat recorded 24 mentions for Enovis and 1 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 0.67 beat Enovis' score of 0.47 indicating that MiniMed Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiniMed Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enovis 3 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, LIVN or ENOV?

LivaNova has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.04 -$242.47M $3.38 22.63 Enovis $2.25B 0.62 -$1.18B -$19.26 N/A

Is LIVN or ENOV more profitable?

LivaNova has a net margin of 12.82% compared to Enovis' net margin of -47.96%. LivaNova's return on equity of 16.35% beat Enovis' return on equity. Company Net Margins Return on Equity Return on Assets LivaNova 12.82% 16.35% 7.76% Enovis -47.96% 12.03% 4.91%

Does the media refer more to LIVN or ENOV?

In the previous week, Enovis had 9 more articles in the media than LivaNova. MarketBeat recorded 24 mentions for Enovis and 15 mentions for LivaNova. LivaNova's average media sentiment score of 0.76 beat Enovis' score of 0.47 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 5 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enovis 3 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, ENOV or ITGR?

Integer has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enovis $2.25B 0.62 -$1.18B -$19.26 N/A Integer $1.85B 2.29 $102.81M $3.66 34.18

Is ENOV or ITGR more profitable?

Integer has a net margin of 6.97% compared to Enovis' net margin of -47.96%. Integer's return on equity of 12.79% beat Enovis' return on equity. Company Net Margins Return on Equity Return on Assets Enovis -47.96% 12.03% 4.91% Integer 6.97% 12.79% 6.48%

Does the media prefer ENOV or ITGR?

In the previous week, Enovis had 8 more articles in the media than Integer. MarketBeat recorded 24 mentions for Enovis and 16 mentions for Integer. Integer's average media sentiment score of 0.74 beat Enovis' score of 0.47 indicating that Integer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 3 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Integer 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Is ENOV or HAE more profitable?

Haemonetics has a net margin of 7.12% compared to Enovis' net margin of -47.96%. Haemonetics' return on equity of 27.55% beat Enovis' return on equity. Company Net Margins Return on Equity Return on Assets Enovis -47.96% 12.03% 4.91% Haemonetics 7.12% 27.55% 9.65%

Does the media prefer ENOV or HAE?

In the previous week, Haemonetics had 4 more articles in the media than Enovis. MarketBeat recorded 28 mentions for Haemonetics and 24 mentions for Enovis. Haemonetics' average media sentiment score of 0.62 beat Enovis' score of 0.47 indicating that Haemonetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 3 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Haemonetics 6 Very Positive mention(s) 3 Positive mention(s) 13 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Enovis (ENOV) Competitors

$24.25 -2.36 (-8.87%)

As of 03:58 PM Eastern

Compare

ENOV vs. TFX, MMED, LIVN, ITGR, and HAE

Should you buy Enovis stock or one of its competitors? Enovis's main competitors and comparable companies include Teleflex (TFX), MiniMed Group (MMED), LivaNova (LIVN), Integer (ITGR), and Haemonetics (HAE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Enovis compare to Teleflex?

Enovis (NYSE:ENOV) and Teleflex (NYSE:TFX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Enovis has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market. Comparatively, Teleflex has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Teleflex has lower revenue, but higher earnings than Enovis. Teleflex is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.62	-$1.18B	-$19.26	N/A
Teleflex	$1.99B	2.95	-$905.64M	-$23.29	N/A

98.5% of Enovis shares are held by institutional investors. Comparatively, 95.6% of Teleflex shares are held by institutional investors. 2.9% of Enovis shares are held by company insiders. Comparatively, 0.7% of Teleflex shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Teleflex has a net margin of -39.67% compared to Enovis' net margin of -47.96%. Enovis' return on equity of 12.03% beat Teleflex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-47.96%	12.03%	4.91%
Teleflex	-39.67%	11.93%	5.44%

Enovis presently has a consensus target price of $42.00, indicating a potential upside of 73.20%. Teleflex has a consensus target price of $150.50, indicating a potential upside of 13.45%. Given Enovis' stronger consensus rating and higher probable upside, research analysts clearly believe Enovis is more favorable than Teleflex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Teleflex	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42

In the previous week, Teleflex had 3 more articles in the media than Enovis. MarketBeat recorded 27 mentions for Teleflex and 24 mentions for Enovis. Teleflex's average media sentiment score of 0.56 beat Enovis' score of 0.47 indicating that Teleflex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	3 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teleflex	8 Very Positive mention(s)	3 Positive mention(s)	11 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Enovis beats Teleflex on 10 of the 17 factors compared between the two stocks.

How does Enovis compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and Enovis (NYSE:ENOV) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

98.5% of Enovis shares are held by institutional investors. 2.9% of Enovis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MiniMed Group has a net margin of 0.00% compared to Enovis' net margin of -47.96%. Enovis' return on equity of 12.03% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MiniMed Group	N/A	N/A	N/A
Enovis	-47.96%	12.03%	4.91%

MiniMed Group has higher revenue and earnings than Enovis. MiniMed Group is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiniMed Group	$3.10B	1.77	-$333M	-$0.68	N/A
Enovis	$2.25B	0.62	-$1.18B	-$19.26	N/A

MiniMed Group currently has a consensus target price of $21.62, indicating a potential upside of 10.85%. Enovis has a consensus target price of $42.00, indicating a potential upside of 73.20%. Given Enovis' higher probable upside, analysts plainly believe Enovis is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Enovis	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

In the previous week, Enovis had 23 more articles in the media than MiniMed Group. MarketBeat recorded 24 mentions for Enovis and 1 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 0.67 beat Enovis' score of 0.47 indicating that MiniMed Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiniMed Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enovis	3 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

MiniMed Group beats Enovis on 8 of the 15 factors compared between the two stocks.

How does Enovis compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Enovis (NYSE:ENOV) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

LivaNova has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Enovis has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market.

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 0.4% of LivaNova shares are owned by insiders. Comparatively, 2.9% of Enovis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

LivaNova presently has a consensus price target of $83.50, indicating a potential upside of 9.18%. Enovis has a consensus price target of $42.00, indicating a potential upside of 73.20%. Given Enovis' higher probable upside, analysts plainly believe Enovis is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73
Enovis	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

LivaNova has a net margin of 12.82% compared to Enovis' net margin of -47.96%. LivaNova's return on equity of 16.35% beat Enovis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
Enovis	-47.96%	12.03%	4.91%

LivaNova has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.04	-$242.47M	$3.38	22.63
Enovis	$2.25B	0.62	-$1.18B	-$19.26	N/A

In the previous week, Enovis had 9 more articles in the media than LivaNova. MarketBeat recorded 24 mentions for Enovis and 15 mentions for LivaNova. LivaNova's average media sentiment score of 0.76 beat Enovis' score of 0.47 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	5 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enovis	3 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

LivaNova beats Enovis on 10 of the 17 factors compared between the two stocks.

How does Enovis compare to Integer?

Enovis (NYSE:ENOV) and Integer (NYSE:ITGR) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

98.5% of Enovis shares are owned by institutional investors. Comparatively, 99.3% of Integer shares are owned by institutional investors. 2.9% of Enovis shares are owned by insiders. Comparatively, 1.1% of Integer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Enovis had 8 more articles in the media than Integer. MarketBeat recorded 24 mentions for Enovis and 16 mentions for Integer. Integer's average media sentiment score of 0.74 beat Enovis' score of 0.47 indicating that Integer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	3 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Integer	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Enovis currently has a consensus target price of $42.00, indicating a potential upside of 73.20%. Integer has a consensus target price of $109.86, indicating a potential downside of 12.18%. Given Enovis' stronger consensus rating and higher probable upside, equities research analysts clearly believe Enovis is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

Enovis has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market. Comparatively, Integer has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Integer has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.62	-$1.18B	-$19.26	N/A
Integer	$1.85B	2.29	$102.81M	$3.66	34.18

Integer has a net margin of 6.97% compared to Enovis' net margin of -47.96%. Integer's return on equity of 12.79% beat Enovis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-47.96%	12.03%	4.91%
Integer	6.97%	12.79%	6.48%

Summary

Integer beats Enovis on 9 of the 16 factors compared between the two stocks.

How does Enovis compare to Haemonetics?

Enovis (NYSE:ENOV) and Haemonetics (NYSE:HAE) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

In the previous week, Haemonetics had 4 more articles in the media than Enovis. MarketBeat recorded 28 mentions for Haemonetics and 24 mentions for Enovis. Haemonetics' average media sentiment score of 0.62 beat Enovis' score of 0.47 indicating that Haemonetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	3 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Haemonetics	6 Very Positive mention(s)	3 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Haemonetics has lower revenue, but higher earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.62	-$1.18B	-$19.26	N/A
Haemonetics	$1.33B	2.96	$97.31M	$2.04	42.52

Haemonetics has a net margin of 7.12% compared to Enovis' net margin of -47.96%. Haemonetics' return on equity of 27.55% beat Enovis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-47.96%	12.03%	4.91%
Haemonetics	7.12%	27.55%	9.65%

Enovis presently has a consensus price target of $42.00, indicating a potential upside of 73.20%. Haemonetics has a consensus price target of $90.89, indicating a potential upside of 4.78%. Given Enovis' higher possible upside, research analysts plainly believe Enovis is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Haemonetics	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Enovis has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market. Comparatively, Haemonetics has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

98.5% of Enovis shares are owned by institutional investors. Comparatively, 99.7% of Haemonetics shares are owned by institutional investors. 2.9% of Enovis shares are owned by insiders. Comparatively, 2.1% of Haemonetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Haemonetics beats Enovis on 12 of the 17 factors compared between the two stocks.

Get Enovis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENOV vs. The Competition

Export

Metric	Enovis	Healthcare Equipment & Supplies Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.53B	$5.82B	$7.02B	$24.19B
Dividend Yield	N/A	1.78%	2.58%	3.69%
P/E Ratio	-1.26	24.71	269.19	29.02
Price / Sales	0.62	61.03	588.76	20.30
Price / Cash	0.99	33.55	28.89	19.37
Price / Book	0.93	6.21	11.27	4.91
Net Income	-$1.18B	$147.87M	$3.45B	$1.06B
7 Day Performance	-22.82%	3.40%	3.56%	1.30%
1 Month Performance	-6.06%	1.66%	-0.58%	2.29%
1 Year Performance	-14.88%	6.26%	77.52%	19.89%

Enovis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENOV Enovis	4.5287 of 5 stars	$24.25 -8.9%	$42.00 +73.2%	-6.3%	$1.53B	$2.25B	N/A	7,802	Earnings Report Analyst Forecast
TFX Teleflex	3.8642 of 5 stars	$139.86 +2.3%	$148.90 +6.5%	+13.4%	$6.05B	$1.99B	N/A	15,500	Earnings Report Dividend Announcement Analyst Forecast High Trading Volume
MMED MiniMed Group	2.3827 of 5 stars	$19.10 +5.8%	$21.62 +13.2%	N/A	$5.36B	$3.10B	N/A	8,000
LIVN LivaNova	3.0876 of 5 stars	$82.46 +2.9%	$81.38 -1.3%	+56.1%	$4.40B	$1.39B	42.29	3,300	Positive News Earnings Report
ITGR Integer	2.4026 of 5 stars	$124.45 +2.7%	$103.71 -16.7%	+17.5%	$4.12B	$1.85B	31.03	11,000	Earnings Report High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ENOV) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enovis (ENOV) Competitors